Silo Pharma, Inc.SILO
Price (close)
$1.75
Market cap
$2.8M
P/E
—
Revenue (TTM)
$54,077
Net income
-$4.5M
Dividend yield
—
1-year total return
-84.3%
Net margin
-8269.5%
Revenue growth
-25.0%
Debt / equity
—
What Silo Pharma, Inc. does.
are a developmental stage biopharmaceutical and cryptocurrency company. Our therapeutics focus is on developing novel therapeutics that
address underserved conditions including PTSD, stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases.
We are focused on developing novel therapies that include conventional drugs and psychedelic formulations. The Company’s lead program,
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $40,923 | — | $72,102 | $72,102 | $72,102 | $72,102 |
| Net income | -$3.0M | $3.9M | -$3.9M | -$3.7M | -$4.4M | -$4.2M |
More on SILO.
- Silo Pharma, Inc. summary
- Silo Pharma, Inc. financial statements
- Silo Pharma, Inc. key metrics
- Silo Pharma, Inc. health scores and style box
- Silo Pharma, Inc. earnings
- Silo Pharma, Inc. dividends
- Silo Pharma, Inc. valuation
- Silo Pharma, Inc. ownership and insiders
- Silo Pharma, Inc. peers
Figures from Silo Pharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.